This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Mar;13(3):134-5.

doi: 10.1038/nrclinonc.2016.9. Epub 2016 Jan 27.

Haematological cancer: Good omens - SIRIUS's glow is auspicious for daratumumab

PMID: 26813937
DOI: 10.1038/nrclinonc.2016.9

Comment

Haematological cancer: Good omens - SIRIUS's glow is auspicious for daratumumab

David Killock. Nat Rev Clin Oncol. 2016 Mar.

. 2016 Mar;13(3):134-5.

doi: 10.1038/nrclinonc.2016.9. Epub 2016 Jan 27.

Author

PMID: 26813937
DOI: 10.1038/nrclinonc.2016.9

No abstract available

PubMed Disclaimer

Comment on

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Lonial S, et al. Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7. Lancet. 2016. PMID: 26778538 Clinical Trial.

Similar articles

Daratumumab in multiple myeloma.
Rajkumar SV. Rajkumar SV. Lancet. 2016 Apr 9;387(10027):1490-1492. doi: 10.1016/S0140-6736(15)01226-X. Epub 2016 Jan 7. Lancet. 2016. PMID: 26778537 No abstract available.
[Daratumumab for multiple myeloma].
Croizier C, Bailly S. Croizier C, et al. Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24. Bull Cancer. 2018. PMID: 30430991 Review. French.
Daratumumab monotherapy for relapsed POEMS syndrome.
Dima D, Valent J, Khouri J. Dima D, et al. Am J Hematol. 2023 Nov;98(11):E291-E294. doi: 10.1002/ajh.27050. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548551 No abstract available.
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R. Minarik J, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019. PMID: 30397362
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
Robak P, Robak T. Robak P, et al. BioDrugs. 2016 Apr;30(2):87-93. doi: 10.1007/s40259-016-0165-6. BioDrugs. 2016. PMID: 26927803 Review.

See all similar articles

References

1. Lancet. 2016 Apr 9;387(10027):1551-60 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information